Klebsiella pneumoniae Community Acquired Infections Surveillance and Vaccine Development (Kleb-CASAVA)

Funder
MRC (via UKRI) (grant number: UKRI1008)
NAFOSTED-Vietnam

Lead Principal Investigator
Duy Pham

Sites
1. Hospital for Tropical Diseases
2. Cho Ray General Hospital
3. National Hospital for Tropical Diseases
4. Ho Chi Minh Center for Disease Control

Timeline
July 2024 – February 2028

 

 

In this Kleb-CASAVA project, we will integrate patient-oriented surveillance and vaccine development to combat community-acquired Kp infections in Vietnam.

Background

Klebsiella pneumoniae (Kp) is a commensal bacterium commonly found in the human gut, nasopharynx and skins. However, it can also cause severe infections, particularly among those with comorbidities and immunocompromised conditions. The global health threat posed by Kp is recognized by the World Health Organization and international health agencies due to its escalating and challenging-to-control nature. In Vietnam and Southeast Asia, there has been a concerning rise in severe Kp infections, especially among the elderly.

Two major pathotypes of Kp exist: classical Kp (cKp) and hypervirulent Kp (hvKp). cKp is known for its high antimicrobial resistance (AMR) and is a frequent cause of hospital-acquired infections among immunocompromised individuals. In contrast, hvKp is characterized by numerous virulence factors and its ability to cause severe invasive community-acquired infections, even in healthy individuals. Both pathotypes have been identified in Vietnam, posing a significant threat for the emergence of strains exhibiting both AMR and hypervirulence.

While hospital-acquired Kp infections have received significant attention, leading to ongoing improvements in infection control and antimicrobial stewardship programs in Vietnam, the emergence of Kp, especially hvKp, in communities is less understood. Research into community-acquired Kp infections faces two main interlinked challenges. Firstly, the current hospital surveillance system is isolate-based and cannot effectively distinguish community-acquired infections, resulting in a poor understanding of at-risk populations, disease sources, and drivers of transmission within communities. Secondly, research capacity to develop effective preventive measures such as vaccines is limited, partly due to gaps in understanding disease and pathogen characteristics.

Aims

In this Kleb-CASAVA project, we will integrate patient-oriented surveillance and vaccine development to combat community-acquired Kp infections in Vietnam.

We will define the epidemiological and clinical features of community-acquired Kp infections. To achieve this, we will conduct a patient-focused hospital study in three national and provincial hospitals in Ho Chi Minh City (HCMC) and Ha Noi (43EN study). This study will identify all cases of community-acquired Kp infections and characterize their incidence, AMR and genotypic profiles, clinical features and outcomes.

Furthermore, we will estimate the prevalence of Kp carriage and quantify the transmission rates of Kp in the community. We will collaborate with HCM Center for Disease Control (HCDC) to enroll households of the hospitalized cases and independent community households in HCMC to quantify transmission rates of Kp (both cKp and hvKp) in the community (44EN study). Additionally, metadata and gut microbiota characterization from patients and household members will help identify potential risk factors for Kp colonization and infection.

We will also assess the human immune responses to Kp antigens among patients with bloodstream infections and their correlation with treatment outcomes. By collaborating with the University of Science in HCMC, we will measure antibody and T cell responses to candidate proteins among patients with bloodstream infections and their household members, and correlate these data with disease outcomes (survival, severity score, length of hospital stays). This investigation will identify robust candidates associated with enhanced survival for further development of vaccines and monoclonal antibodies.

The study findings will be shared with local stakeholders and policy makers, facilitating the development of local treatment guidelines and targeted public health interventions. Through this collaborative and strategic project, we will enhance research capacity in Vietnam to address public health challenges posed by Kp and other emerging pathogens. The project findings will contribute to global efforts in understanding community transmission dynamics of Kp and advance the development of targeted therapeutics and vaccines.

Local Training and Capacity Building Plan

  • PhD training
    • Nguyen Pham Nhu Quynh, DPhil student, Oxford University, UK
    • Bui Thi Hong Hanh, DPhil student, University of Medicine and Pharmacy, HCMC, Vietnam
    • Tran Thi Ngoc Dung, DPhil student, University of Medicine and Pharmacy, University of Science, HCMC, Vietnam
  • Bioinformatics training
    • 1st workshop November 2025
    • 2nd workshop November 2026
    • Participants from local hospitals and institutions in Vietnam
  • Statistics and mathematical modelling training
    • Workshop June 2026
    • Participants from local hospitals and institutions in Vietnam

 

PELAJARI SELENGKAPNYA

Related

OUCRU logo dark

Dr Bui Thi Hong Hanh

OUCRU logo dark

Dr Ho Dang Trung Nghia

OUCRU logo dark

Dr Ho Quang Minh

OUCRU logo dark

Dr Le Buu Chau

OUCRU logo dark

Dr Le Hong Nga

OUCRU logo dark

Dr Le Thi Diem

OUCRU logo dark

Dr Van Dinh Trang

OUCRU logo dark

Dr. François Blanquart

OUCRU logo dark

Dr. Truong Thi Thanh Lan

OUCRU logo dark

Dr. Truong Thien Phu

OUCRU logo dark

Prof Nguyen Duc Hoang

OUCRU logo dark

Prof Phan Thi Phuong Trang

Susanna Dunachie

Professor Susanna Dunachie

HCDC

Ho Chi Minh Centre For Disease Control (HCDC)

HTD-updated logo

Hospital For Tropical Diseases

NHTDw

National Hospital of Tropical Diseases

oxford logo

University of Oxford

VNU

Vietnam National University Ho Chi Minh City